Cargando…
Worldwide experience with biosimilar development
Limited access for high-quality biologics due to cost of treatment constitutes an unmet medical need in the US and other regions of the world. The term “biosimilar” is used to designate a follow-on biologic that meets extremely high standards for comparability or similarity to the originator biologi...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092622/ https://www.ncbi.nlm.nih.gov/pubmed/21441787 http://dx.doi.org/10.4161/mabs.3.2.15005 |